NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
48.28
-0.03 (-0.06%)
At close: 4:02PM EDT

48.00 -0.28 (-0.58%)
Pre-market: 9:03AM EDT

Stock chart is not supported by your current browser
Previous close48.31
Open0.00
Bid47.97 x 3200
Ask48.02 x 1100
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volume1,428,198
Market cap114.384B
Beta (3Y monthly)0.78
PE ratio (TTM)19.61
EPS (TTM)2.46
Earnings dateN/A
Forward dividend & yield1.25 (2.59%)
Ex-dividend date2019-03-22
1y target est53.90
Trade prices are not sourced from all markets
  • Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
    Zacks4 days ago

    Gilead-Galapagos Ink $5.1B Deal for Additional Compounds

    Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.

  • Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
    Zacks7 days ago

    Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

    Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

  • MarketWatch7 days ago

    Sunnova Energy to offer 17.6 million shares in IPO, priced at $16 to $18 each

    Sunnova Energy International Inc. set terms for its planned initial public offering, saying in a regulatory filing it plans to offer 17.6 million shares priced at $16 to $18 each. The Houston-based solar energy company would raise $316.8 million at the top of that range. Seven banks are underwriting the deal, led by BofA Merrill Lynch, JPMorgan and Goldman Sachs. Proceeds will be used to pay down debt and for general corporate purposes.

  • Reuters - UK Focus7 days ago

    UPDATE 2-Swiss stocks keep a lid on European shares as pharma drag lingers

    European shares were little changed on Friday as drugmakers came under pressure on worries the U.S. government may intervene over high drug prices, while Federal Reserve chairman Jerome Powell's dovish comments helped limit losses. The pan-European STOXX 600 index ended flat but broke a five-week winning streak as regional equities failed to take advantage of the Fed's accommodative stance this week. Swiss stocks underperformed, sliding more than 1% as drugmakers including Roche Holdings, Novartis and Novo Nordisk fell more than 2%.

  • Reuters - UK Focus8 days ago

    LIVE MARKETS-Closing snapshot: Europe closes at 2-week low

    * European stocks fall after pharma stocks slide * STOXX 600 closes down 0.1%, healthcare stocks weigh: Siemens Healthineers -6% * Autos drag Germany's DAX 0.3% lower * UK housebuilders rise on upbeat survey * Indivior soars after lifting profit guidance, Reckitt rises after U.S. settlement Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: thyagaraju.adinarayan.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: EUROPE CLOSES AT 2-WEEK LOW (1601 GMT) Profit taking in pharma stocks has derailed the Powell-induced gains, pushing the STOXX 600 into the red in late afternoon trade and to its lowest close since June 28.

  • Reuters - UK Focus8 days ago

    LIVE MARKETS-Health check for pharma as U.S. shifts focus to high drug prices

    * European stocks fall after pharma stocks slide * STOXX 600 down 0.2%, healthcare stocks weigh: Siemens Healthineers -7% * Autos drag Germany's DAX 0.3% lower * UK housebuilders rise on upbeat survey * Indivior soars after lifting profit guidance, Reckitt rises after U.S. settlement Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: thyagaraju.adinarayan.thomsonreuters.com@reuters.net HEALTH CHECK FOR PHARMA AS U.S. SHIFTS FOCUS TO HIGH DRUG PRICES (1527 GMT) European pharma stocks are taking a hit this afternoon on worries that U.S. Congress will now look at doing something about high drug prices.

  • Reuters - UK Focus8 days ago

    UPDATE 2-European shares dip on pharma drag as Fed optimism sizzles out

    European shares closed at a two-week low on Thursday weighed down by pharma stocks on worries that U.S. government may intervene on high drug prices, while optimism from the Federal Reserve's dovish stance faded away. The pan-European stocks benchmark rallied earlier in the day on remarks from Fed Chair Jerome Powell but reversed course in late afternoon trading to close 0.1% lower. The White House announced that it was ditching its push for changes to the pharma rebate structure, providing some relief to health insurance companies but hurting drugmakers, including those in Europe.

  • Court Ruling Topples Trump Order, No Price Display in TV Ads
    Zacks9 days ago

    Court Ruling Topples Trump Order, No Price Display in TV Ads

    The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

  • Novo Nordisk Reports Encouraging Data From Hemophilia Studies
    Zacks10 days ago

    Novo Nordisk Reports Encouraging Data From Hemophilia Studies

    Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.

  • Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?
    Simply Wall St.10 days ago

    Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?

    Dividend paying stocks like Novo Nordisk A/S (CPH:NOVO B) tend to be popular with investors, and for good reason...

  • A Look at NVO’s Spending and Earnings in Fiscal 2019
    Market Realist18 days ago

    A Look at NVO’s Spending and Earnings in Fiscal 2019

    In the first-quarter earnings investor presentation, Novo Nordisk (NVO) guided for YoY operating profit growth of 2% to 5%.

  • How NVO’s Revenues Are Trending in Fiscal 2019
    Market Realist18 days ago

    How NVO’s Revenues Are Trending in Fiscal 2019

    Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.

  • What Analysts Recommend for GlaxoSmithKline and Novo Nordisk
    Market Realist18 days ago

    What Analysts Recommend for GlaxoSmithKline and Novo Nordisk

    GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.

  • Lilly's Study on Higher Doses of Trulicity Meets Endpoint
    Zacks22 days ago

    Lilly's Study on Higher Doses of Trulicity Meets Endpoint

    Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.

  • Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
    Zacks23 days ago

    Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

    Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

  • The 10 Biggest Biotech Stocks
    Motley Fool24 days ago

    The 10 Biggest Biotech Stocks

    Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

  • Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
    Zacks28 days ago

    Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

    Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

  • Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
    Zacks28 days ago

    Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

    Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

  • Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
    Zacks29 days ago

    Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs

    Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

  • NVS or NVO: Which Is the Better Value Stock Right Now?
    Zackslast month

    NVS or NVO: Which Is the Better Value Stock Right Now?

    NVS vs. NVO: Which Stock Is the Better Value Option?

  • Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
    Zackslast month

    Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients

    Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

  • Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
    MarketWatchlast month

    Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

    Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.

  • MarketWatchlast month

    FDA approves non-insulin Type 2 diabetes drug for kids, the first to hit market in 20 years

    The U.S. Food and Drug Administration on Monday approved Novo Nordisk's Victoza, a liraglutide injection, for the treatment of young patients 10 years or older with Type 2 diabetes. Although Victoza has been FDA-approved to treat adults with Type 2 diabetes since 2010, it is the only non-insulin drug approved for children other than metformin, which was approved for pediatric use in 2000. "Victoza has now been shown to improve blood sugar control in pediatric patients with Type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease," said Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. Type 2 diabetes occurs when the pancreas is unable to make enough insulin to keep blood sugar at normal levels. It's the most common form of diabetes, normally occurring in patients 45 years or older. However, in the past two decades, its prevalence among younger patients has dramatically risen. More than 5,000 new cases of Type 2 diabetes are now diagnosed each year in the U.S. among people younger than age 20, according to the Centers for Disease and Control and Prevention. Shares of Novo Nordisk have gained 10.8% so far this year, while the SPDR S&P Pharmaceuticals ETF has gained 3%. The Dow Jones Industrial Average has gained 11.8% and the S&P 500 has gained 15.3%.

  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zackslast month

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes